Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
Pharmanovia Expands Strategic Collaboration with M8 Pharmaceuticals in Latin America
Basildon (UK), 20 July, 2021 – m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement...
More informationPharmanovia Announces CEO Transition Plan
Amit Patel is retiring as CEO, will transition to the Advisory Committee James Burt will take...
More informationPharmanovia Promotes Alessandro Insalata to Chief Commercial Officer
Basildon (UK), 3 June 2021 – Pharmanovia, the original medicines specialist globally announced the promotion of...
More informationThe Original Medicines Specialist Rebrands to Pharmanovia
Basildon (UK), 4 May 2021 – Atnahs, the original medicines specialist backed by PE investor Triton Partners,...
More informationAtnahs Appoints New Chief Financial Officer
Basildon (UK), 22 March 2021 – Atnahs has appointed Felipe Florez to the position of Chief Financial...
More informationAtnahs Acquires Rights to Valium®
Basildon (UK), 1 December 2020 – Atnahs (“Atnahs”), has acquired the commercial rights for Valium® (Diazepam) in...
More informationCOVID-19: Atnahs Continues Operations
Basildon (UK), 19 March 2020 – On 11 March 2020 the World Health Organization (WHO) declared...
More informationAtnahs Acquires Rights to Rocaltrol®, An Established Brand in Women’s Health
Basildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company,...
More informationAtnahs Buys Takeda Out of License Agreement for Bonviva® in Asia
Basildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for...
More information